Casdatifan - Arcus Biosciences
Alternative Names: AB-521; HIF-2a inhibitor - Arcus BiosciencesLatest Information Update: 10 Mar 2025
Price :
$50 *
At a glance
- Originator Arcus Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Renal cell carcinoma; Solid tumours
- Phase I Cancer
- Preclinical Liver cancer
Most Recent Events
- 10 Mar 2025 Efficacy data from the phase I/Ib ARC-20 trial in renal cell carcinoma released by Arcus Biosciences
- 15 Feb 2025 Updated efficacy and adverse events data from the phase I/Ib ARC-20 trial in renal cell carcinoma released by Arcus Biosciences
- 15 Feb 2025 AstraZeneca plans a phase Ib trial of casdatifan in combination with volrustomig